• Latest Posts

How could the HIV Field benefit from Gilead’s new €2M Research Grants?

Mologen Joins the Rapidly Growing List of EU Partners with the No#1 US Cancer Hospital

A Phase II HIV Antiviral from France Has Promising Results

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine


Theravectys’ HIV Cure on the Road to Success

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine